在一项随机对照试验中,在轻度至中度勃起功能障碍患者中,Hongjing I颗粒,一种草药的有效性
Run-Nan Xu1,2, Jun Guo3, Chun-He Zhang4
1Department of Urology, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Frontiers in pharmacology
|January 8, 2025
概括
在一项随机试验中,Hongjing I颗粒 (HJIG) 显著改善了勃起功能障碍 (ED) 症状. 这种传统中医药为轻度至中度勃起障碍提供了有前途的治疗方法.
科学领域:
- 综合医学是一个整体医学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 传统中国医药 传统中国医药
背景情况:
- 洪京I颗粒 (HJIG) 是一种中国传统医药,在中国治疗勃起功能障碍 (ED) 已有20多年的历史.
- 勃起障碍是影响全球许多男性的普遍疾病,需要多种不同的治疗选择.
研究的目的:
- 评估HJIG在患有轻度至中度ED的患者中的有效性和安全性.
- 在严格的临床试验环境中,比较HJIG与安慰剂的疗效.
主要方法:
- 一个多中心,双盲,随机,安慰剂对照试验,涉及100名患有轻度至中度ED的患者.
- 参与者根据传统中医的基准诊断出qi缺乏和血液静止.
- 治疗持续时间为8周,主要结局包括国际勃起功能指数-勃起功能域 (IIEF-EF) 和性接触概况 (SEP) 评分.
主要成果:
- 与安慰剂相比,HJIG显著改善了IIEF-EF评分 (平均变化7.80与3.33相比,P<0.001).
- 在SEP3得分 (P = 0.05) 和传统中医症状得分中观察到有统计学意义的改善.
- 在HJIG或安慰剂组中没有报告任何不良事件.
结论:
- 洪京I颗粒在改善轻度至中度勃起障碍患者的症状方面表现出显著的有效性.
- 建议进行进一步的扩展随机试验,以验证这些发现并支持更广泛的临床应用.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K